NeuroTraq is developing Bio-signal Analysis Monitoring (BAM) technology to accurately characterize conditions like pain, stress, depression, or post traumatic stress disorder that medical technology currently cannot objectively monitor.  Understanding such complex neurophysiological states requires concurrent multivariate assessment of many parameters, which the proprietary BAM processing methods make possible in near-real time. 

BAM will accurately identify and depict complex neurophysiological conditions for clinicians, permitting efficient diagnoses and optimized medical protocols resulting in faster, safer, and better treatment outcomes.  This will create important new paradigms for medical research, diagnosis and treatment in strategic clinical markets.

NeuroTraq is currently studying BAM methods to reveal hidden early stage cardiovascular (CV) problems.  The objective is to detect CV issues when the treatment prognosis is more favorable and before sufficient damage occurs to make such conditions belatedly apparent to conventional monitoring methods.

NEWS:  Our PCT patent on methods for concurrent electical bio-signal monitoring in the presence of electrical stimulation has been approved as of  March 2010.

BAM technology is protected by recent patents filed by NeuroTraq founder, John Bell.

Executive Support sought

Introduction

BAM Technology

NeuroTraq is seeking experienced senior executives to help take us to the next level: 
Learn More

TOP

 

 

                    Copyright 2006,  NeuroTraq, Inc.  All rights reserved.               

NeuroTraq, EASE, the NeuroTraq logo, and "New Paradigms in Clinical Technology" are trademarks of NeuroTraq, Incorporated.

NeuroTraq is about one year from commercial prototypes.  NeuroTraq now needs an experienced medical executive team to secure NTQ financially and provide the guidance needed to achieve full commercialization of these products that can significantly impact several critical areas of cardiovascular and neurological diagnosis and treatment.

Contact Information: John Bell, President
MCPC 320-F
9750 S 300W
Sandy, Utah  84070
    80I-9I8-3478